We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

Download Mobile App





New Purpose-Built COVID-19 LIMS Solution Jump-Starts COVID-19 Testing and Research

By LabMedica International staff writers
Posted on 11 May 2020
Print article
Illustration
Illustration
A new purpose-built COVID-19 laboratory information management system (LIMS) solution can jump-start the ability of laboratories everywhere to enter biospecimens into a biobank and rapidly begin conducting COVID-19-related testing and research.

The new COVID-19 Biobanking Accelerator is built on the LabVantage Solutions, Inc.’s (Somerset, NJ, USA) industry-leading LIMS and Biobanking platforms used by clinical laboratories around the globe. Delivered as a comprehensive Software-As-A-Service (SaaS) solution, the LabVantage COVID-19 Biobanking Accelerator requires no infrastructure investment. Being pre-configured means minimal implementation time is needed with a go-live start possible in less than four weeks.

The LIMS Accelerator includes full biobanking capabilities and COVID-19 extraction and testing workflows with related master data for rapid use. It incorporates multiple protocols defined by the CDC for COVID-19 testing, and it can easily accommodate the addition of standard and customer-determined protocols for testing using a variety of approaches, such as RT-PCR, isothermal nucleic acid amplification and serology.

“Widespread laboratory testing is a critical component in the battle to control the coronavirus pandemic sweeping the globe. At LabVantage, we mobilized our decades of expertise to rapidly deliver a new purpose-built Biobanking LIMS to support COVID-19 testing and research,” said LabVantage CEO John Heiser. “It incorporates our deep knowledge of biobanking along with numerous features designed to make it easy for laboratories to acquire, implement and use the most powerful LIMS on the market for their COVID-19 testing. The LIMS Accelerator is also scalable, an important attribute as testing volumes escalate. Our outstanding service team stands ready to help customers begin using the package almost immediately. We are honored to have the opportunity to contribute to the laboratory testing and research that is critical to controlling and ultimately eliminating this devastating pandemic.”

Related Links:
LabVantage Solutions, Inc.


Print article

Channels

Microbiology

view channel
Image: Stenotrophomonas maltophilia colonies on sheep blood agar. Cultivation 48 hours in an aerobic atmosphere, 37 °C (Photo courtesy of microbiologyinpictures).

Global Spread of the Multi-Resistant Pathogen Stenotrophomonas Maltophilia Revealed

Stenotrophomonas maltophilia strains occur in several natural and human associated ecosystems. The bacterium was long regarded as relatively unproblematic, but is now considered to be one of the most feared... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.